Restriction of drinking water abrogates splanchnic vasodilation and portal hypertension in portal vein-ligated rats

Pharmacology

Volumn 83, Issue 1, 2008, Pages 26-32

  Heinemann, Akos ^a   Schuligoi, Rufina ^a   Lippe, Irmgard T ^a   Stauber, Rudolf E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Blood flow; Hyporesponsiveness; Mesenteric artery; Portal hypertension; Vasopressin

Indexed keywords

ARGIPRESSIN; DRINKING WATER; VASOPRESSIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DEHYDRATION; DRUG EFFECT; FLUID BALANCE; HEMODYNAMICS; HYPEREMIA; MALE; MESENTERIC ARTERY; MESENTERY BLOOD FLOW; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SPLANCHNIC BLOOD FLOW; SPRAGUE DAWLEY RAT; ULTRASOUND; VASODILATATION; VASOPRESSIN RELEASE; VEIN LIGATION; WATER DEPRIVATION;

ANIMALS; ARGININE VASOPRESSIN; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HYPEREMIA; HYPERTENSION, PORTAL; LIGATION; LIVER DISEASES; MALE; MESENTERIC ARTERY, SUPERIOR; PORTAL VEIN; RATS; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION; VASOCONSTRICTOR AGENTS; VASODILATION; VASOPRESSINS; WATER DEPRIVATION;

EID: 55149089486     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167877     Document Type: Article

References (38)

1. Blanchet L, Lebrec D: Changes in splanchnic blood flow in portal hypertensive rats. Eur J Clin Invest 1982;12:327-330.
2. Vorobioff J, Bredfeldt JE, Groszmann RJ: Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-G57.
3. Iwakiri Y, Groszmann RJ: The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-S131.
4. Rodriguez-Vilarrupla A, Fernandez M, Bosch J, Garcia-Pagan JC: Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 2007;6:28-36.
5. Ranek L, Vilstrup H, Iversen J, Petersen P, Milandri M: The effect of continuous vasopressin infusion on splanchnic blood flow, liver function, and portal and central venous pressures in patients with cirrhosis. Scand J Clin Lab Invest 1984;44:251-256.
6. Westaby D, Gimson A, Hayes PC, Williams R: Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. Gut 1988;29:372-377.
7. Yan BM, Lee SS: Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol 2006;20:165-170.
8. Lenz K, Hortnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes AL: Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991;101:1060-1067.
9. Heinemann A, Stauber RE: Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol 1996;24:739-746.
10. Heinemann A, Wachter CH, Holzer P, Fickert P, Stauber RE: Nitric oxide-dependent and -independent vascular hyporeactivity in mesenteric arteries of portal hypertensive rats. Br J Pharmacol 1997;121:1031-1037.
11. Heinemann A, Wachter CH, Fickert P, Trauner M, Stauber RE: Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. Hepatology 1998;28:646-654.
12. Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ, Lee SS: Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005;100:631-635.
13. Heinemann A, Stauber RE: The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats. Eur J Pharmacol 1995;278:87-90.
14. Sikuler E, Groszmann RJ: Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986;250:G205-G212.
15. D'Almeida MS, Gaudin C, Lebrec D: Validation of 1- and 2-mm transit-time ultrasound flow probes on mesenteric artery and aorta of rats. Am J Physiol 1995;268:H1368-H1372.
16. Heinemann A, Wachter CH, Holzer P: Differential regulation of mesenteric and femoral blood flow in the rat as revealed by computerized data acquisition and evaluation. J Auton Pharmacol 1998;18:39-48.
17. Hadengue A, Lee SS, Koshy A, Girod C, Lebrec D: Regional blood flows by the microsphere method: reproducibility in portal hypertensive rats and influence of a portal vein catheter. Proc Soc Exp Biol Med 1988;187:461-468.
18. Bomzon A, Blendis LM: Vascular reactivity in experimental portal hypertension. Am J Physiol 1987;252:G158-G162.
19. Sieber CC, Groszmann RJ: Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-239.
20. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J: Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007;45:495-506.
21. Coll M, Genesca J, Raurell I, Rodriguez-Vilarrupla A, Mejias M, Otero T, Oria M, Esteban R, Guardia J, Bosch J, Martell M: Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. J Hepatol 2008;49:43-51.
22. Iwao T, Toyonaga A, Oho K, Shigemori H, Sakai T, Tayama C, Masumoto H, Sato M, Tanikawa K: Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. J Hepatol 1996;25:491-497.
23. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J: Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-1624.
24. Colle IO, De Vriese AS, Van Vlierberghe HR, Lameire NH, De Vos MM: Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur J Gastroenterol Hepatol 2004;16:139-145.
25. Barrett LK, Singer M, Clapp LH: Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007;35:33-40.
26. Atucha NM, Ortiz MC, Martinez C, Quesada T, Garcia-Estan J: Role of protein kinase C in mesenteric pressor responses of rats with portal hypertension. Br J Pharmacol 1996;118:277-282.
27. Weigert AL, Martin PY, Niederberger M, Higa EM, McMurtry IF, Gines P, Schrier RW: Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology 1995;22:1856-1862.
28. Atucha NM, Shah V, Garcia-Cardena G, Sessa WE, Groszmann RJ: Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology 1996;111:1627-1632.
29. +-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 1992;263:H491-H496.
30. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R: Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998;449:251-276.
31. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D: Altered control of vascular tone by adenosine triphosphatesensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-1023.
32. Wu ZY, Benoit JN: Altered vascular norepinephrine responses in portal hypertensive intestine: role of PKA and guanylate cyclase. Am J Physiol 1997;272:G831-G837.
33. Franchini KG, Cowley AW Jr: Renal cortical and medullary blood flow responses during water restriction: role of vasopressin. Am J Physiol 1996;270:R1257-R1264.
34. Wiest R, Jurzik L, Moleda L, Froh M, Schnabl B, von Horsten S, Scholmerich J, Straub RH: Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol 2006;44:512-519.
35. Wultsch T, Painsipp E, Donner S, Sperk G, Herzog H, Peskar BA, Holzer P: Selective increase of dark phase water intake in neuropeptide-Y Y2 and Y4 receptor knockout mice. Behav Brain Res 2006;168:255-260.
36. Urban JH, Leitermann RJ, DeJoseph MR, Somponpun SJ, Wolak ML, Sladek CD: Influence of dehydration on the expression of neuropeptide Y Y1 receptors in hypothalamic magnocellular neurons. Endocrinology 2006;147:4122-4131.
37. Maeda S, Miyauchi T, Waku T, Koda Y, Kono I, Goto K, Matsuda M: Plasma endothelin-1 level in athletes after exercise in a hot environment: exercise-induced dehydration contributes to increases in plasma endothelin-1. Life Sci 1996;58:1259-1268.
38. Gines P, Wong F, Watson H, Milutinovic S, Ruiz Del Arbol L, Olteanu D: Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48:204-213.